AGI BIOPHARMACEUTICALS
AGI Biopharmaceuticals, Ltd., a European firm that has developed a patented, economic, melanoma vaccine with future multi-cancer application.
AGI BIOPHARMACEUTICALS
Industry:
Biopharma Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2009-01-01
Address:
Ireland, Indiana, United States
Country:
United States
Total Employee:
11+
Status:
Active
Total Funding:
4.71 M USD
Similar Organizations
Circuport
Circuport Circuport System offers an implantable port that provides vascular access systems for hemodialysis patients.
Ichorion Therapeutics
Ichorion Therapeutics is a biopharmaceutical company that develop treatments for rare diseases with unmet medical needs.
Leptos Biomedical
Leptos Biomedical offers a proprietary neuromodulation therapy solution for chronic obesity.
MirImmune
MirImmune is a biopharmaceutical company focused on the development of new and improved immunotherapies for cancer.
Quadriga BioSciences
Quadriga BioSciences is a pharmaceutical company developing proprietary targeted cancer therapies.
Investors List
Mentor Capital Partners
Mentor Capital Partners investment in Venture Round - AGI Biopharmaceuticals
More informations about "AGI Biopharmaceuticals"
AGI Biopharmaceuticals - Funding, Financials, Valuation & Investors
Organization. AGI Biopharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. Highlights. Funding Rounds 1. obfuscated. ... AGI …See details»
AGI Biopharmaceuticals - PitchBook
AGI Biopharmaceuticals General Information Description. Developer of melanoma vaccines. The company caters to the healthcare industry and specializes in developing melanoma vaccines …See details»
AGI Biopharmaceuticals - Products, Competitors, Financials, …
AGI Biopharmaceuticals is a European firm that has developed a patented, economic, melanoma vaccine with future multi-cancer application. Use the CB Insights Platform to explore AGI …See details»
AGI Biopharmaceuticals - Crunchbase
AGI Biopharmaceuticals offers a patented melanoma vaccine with future multi-cancer applications.See details»
AGI Biopharmaceuticals Ltd - Company Profile and News
Company profile page for AGI Biopharmaceuticals Ltd including stock price, company news, executives, board members, and contact informationSee details»
AstraZeneca and Aspen complete agreement for residual rights to ...
Nov 1, 2017 Under the terms of the new agreement, AGI has now acquired the remaining rights to the intellectual property and manufacturing know-how related to the anaesthetic medicines. …See details»
AGI Biopharmaceuticals Stock Price, Funding, Valuation, Revenue ...
See AGI Biopharmaceuticals funding rounds, investors, investments, exits and more. Evaluate their financials based on AGI Biopharmaceuticals's post-money valuation and revenue.See details»
Cancer vaccine - AGI Biopharmaceuticals - AdisInsight
AGI Biopharmaceuticals is developing a vaccine for use in multiple types of cancer. Melanoma is the first cancer being targeted and six studies in human Cancer vaccine - AGI …See details»
Royalty Pharma
We are the world’s largest buyer of biopharmaceutical royalties and a leading funder of innovation in life sciences. Learn more # 1. Buyer of biopharma royalties >$ 30 bn. Announced …See details»
AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS …
Oct 6, 2023 Advances Amgen's Mission to Serve Patients With First-in-Class Rare Disease Medicines. THOUSAND OAKS, Calif., Oct. 6, 2023 /PRNewswire/ -- Amgen (NASDAQ: …See details»
Agi Hamburger, Ph.D. - A2 Biotherapeutics
Agi Hamburger, Ph.D., joined A2 Bio in February 2018 and was one of the company’s first employees. As head of drug discovery, Agi is leading efforts to build a world-class cell therapy …See details»
AGC Biologics Enters Agreement to Acquire Facility in Longmont, CO
(SEATTLE), July 1, 2021 -- AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the signing of a purchase …See details»
AGI Biopharmaceuticals - Updates, News, Events, Signals & Triggers
AGI Biopharmaceuticals offers a patented melanoma vaccine with future multi-cancer applications.See details»
Rapid growth in biopharma: Challenges and opportunities
Dec 1, 2014 Biopharmaceuticals have set new standards for blockbuster drugs as well. Blockbusters are traditionally defined as drugs that have $1 billion or more in annual sales; the …See details»
Major investments in domestic firms to rebuild Canada’s ...
Mar 16, 2021 As a CDMO—a contract development and manufacturing organization—our investment will provide valuable services to support Canadian and foreign biopharmaceutical …See details»
For Biopharma, a Rising Tide—and Choppy Waters | BCG
Jun 23, 2022 Business development puts licensed assets on the R&D conveyor belt, and a process-based organization shepherds them efficiently through development and …See details»
Creating a Winning Biopharma Strategy in the ’20s | BCG
Jan 13, 2020 BCG delivers solutions through leading-edge management consulting, technology and design, and corporate and digital ventures. We work in a uniquely collaborative model …See details»
How biopharma companies can change their business model | BCG
Dec 9, 2021 BCG delivers solutions through leading-edge management consulting, technology and design, and corporate and digital ventures. We work in a uniquely collaborative model …See details»
2024 Biopharma Outlook: 24 Trends, Innovations, and FDA's …
Jan 1, 2024 The collaborative efforts of researchers, industry leaders, and regulatory bodies will shape the trajectory of the biopharmaceutical landscape in 2024 and beyond. FDA's Critical …See details»